1. Home
  2. PKE vs DSGN Comparison

PKE vs DSGN Comparison

Compare PKE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Aerospace Corp.

PKE

Park Aerospace Corp.

HOLD

Current Price

$19.24

Market Cap

381.4M

Sector

Industrials

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.22

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKE
DSGN
Founded
1954
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
381.4M
418.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PKE
DSGN
Price
$19.24
$9.22
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
84.3K
457.9K
Earning Date
01-13-2026
11-05-2025
Dividend Yield
2.55%
N/A
EPS Growth
5.81
N/A
EPS
0.36
N/A
Revenue
$63,128,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$54.48
N/A
Revenue Growth
7.63
N/A
52 Week Low
$11.97
$2.60
52 Week High
$21.52
$9.85

Technical Indicators

Market Signals
Indicator
PKE
DSGN
Relative Strength Index (RSI) 50.59 71.64
Support Level $18.43 $8.21
Resistance Level $19.90 $9.85
Average True Range (ATR) 0.70 0.68
MACD 0.06 0.20
Stochastic Oscillator 60.89 82.97

Price Performance

Historical Comparison
PKE
DSGN

About PKE Park Aerospace Corp.

Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: